Application of Curcumin to Heart Failure Therapy by Targeting Transcriptional Pathway in Cardiomyocytes

DOI DOI Web Site Web Site Web Site ほか3件をすべて表示 一部だけ表示 被引用文献18件 参考文献22件
  • Sunagawa Yoichi
    Human Health Sciences, Graduate School of Medicine, Kyoto University Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka
  • Wada Hiromichi
    Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization
  • Suzuki Hidetoshi
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka
  • Sasaki Hiroki
    Theravalues Corporation
  • Imaizumi Atsushi
    Theravalues Corporation
  • Fukuda Hiroyuki
    Theravalues Corporation
  • Hashimoto Tadashi
    Theravalues Corporation
  • Katanasaka Yasufumi
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka
  • Shimatsu Akira
    Clinical Research Institute, Kyoto Medical Center, National Hospital Organization
  • Kimura Takeshi
    Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
  • Kakeya Hideaki
    Department of System Chemotherapy and Molecular Sciences, Division of Bioinformatics and Chemical Genomics, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Fujita Masatoshi
    Human Health Sciences, Graduate School of Medicine, Kyoto University
  • Hasegawa Koji
    Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization
  • Morimoto Tatsuya
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka

書誌事項

タイトル別名
  • A Novel Drug Delivery System of Oral Curcumin Markedly Improves Efficacy of Treatment for Heart Failure after Myocardial Infarction in Rats

この論文をさがす

抄録

Curcumin is an inhibitor of p300 histone acetyltransferase activity, which is associated with the deterioration of heart failure. We reported that native curcumin, at a dosage of 50 mg/kg, prevented deterioration of the systolic function in rat models of heart failure. To achieve more efficient oral pharmacological therapy against heart failure by curcumin, we have developed a novel drug delivery system (DDS) which markedly increases plasma curcumin levels. At the dosage of 0.5 mg/kg, DDS curcumin but not native curcumin restored left ventricular fractional shortening in post-myocardial infarction rats. Thus, our DDS strategy will be applicable to the clinical setting in humans.

収録刊行物

被引用文献 (18)*注記

もっと見る

参考文献 (22)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ